1
|
Bordoni V, Bibas M, Abbate I, Viola D, Rozera G, Agrati C, Rinaldi A, Amendola A, Ammassari A, Capobianchi MR, Martini F. Bone marrow CD34+ progenitor cells may harbour HIV-DNA even in successfully treated patients. Clin Microbiol Infect 2014; 21:290.e5-8. [PMID: 25658531 DOI: 10.1016/j.cmi.2014.11.003] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/14/2014] [Revised: 09/05/2014] [Accepted: 11/02/2014] [Indexed: 01/23/2023]
Abstract
The issue about bone marrow hematopoietic progenitor cells harbouring HIV-DNA in infected patients is still under scrutiny. We studied nine HIV-infected individuals undergoing bone marrow aspiration for diagnostic purposes. In all patients, even in those receiving successful antiretroviral therapy for several years, HIV-DNA was detected in purified CD34+ lineage-bone marrow progenitor cells. This finding, although not conclusive due to the low number of patients examined, adds further evidence that current treatment strategies may be insufficient to resolve latent infection in bone marrow CD34+ hematopoietic progenitor cells.
Collapse
Affiliation(s)
- V Bordoni
- Cellular Immunology Laboratory, National Institute for Infectious Diseases "Lazzaro Spallanzani" I.R.C.C.S., Rome, Italy.
| | - M Bibas
- Clinical Department, National Institute for Infectious Diseases "Lazzaro Spallanzani" I.R.C.C.S., Rome, Italy
| | - I Abbate
- Virology Laboratory, National Institute for Infectious Diseases "Lazzaro Spallanzani" I.R.C.C.S., Rome, Italy
| | - D Viola
- Cellular Immunology Laboratory, National Institute for Infectious Diseases "Lazzaro Spallanzani" I.R.C.C.S., Rome, Italy
| | - G Rozera
- Virology Laboratory, National Institute for Infectious Diseases "Lazzaro Spallanzani" I.R.C.C.S., Rome, Italy
| | - C Agrati
- Cellular Immunology Laboratory, National Institute for Infectious Diseases "Lazzaro Spallanzani" I.R.C.C.S., Rome, Italy; Virology Laboratory, National Institute for Infectious Diseases "Lazzaro Spallanzani" I.R.C.C.S., Rome, Italy
| | - A Rinaldi
- Cellular Immunology Laboratory, National Institute for Infectious Diseases "Lazzaro Spallanzani" I.R.C.C.S., Rome, Italy
| | - A Amendola
- Virology Laboratory, National Institute for Infectious Diseases "Lazzaro Spallanzani" I.R.C.C.S., Rome, Italy
| | - A Ammassari
- Clinical Department, National Institute for Infectious Diseases "Lazzaro Spallanzani" I.R.C.C.S., Rome, Italy
| | - M R Capobianchi
- Virology Laboratory, National Institute for Infectious Diseases "Lazzaro Spallanzani" I.R.C.C.S., Rome, Italy
| | - F Martini
- Cellular Immunology Laboratory, National Institute for Infectious Diseases "Lazzaro Spallanzani" I.R.C.C.S., Rome, Italy
| |
Collapse
|
2
|
De Nardo P, Oliva A, Giancola ML, Ghirga P, Mencarini P, Bibas M, Nicastri E, Antinori A, Corpolongo A. Haemolytic anaemia after oral artemether-lumefantrine treatment in a patient affected by severe imported falciparum malaria. Infection 2013; 41:863-5. [PMID: 23553281 DOI: 10.1007/s15010-013-0451-x] [Citation(s) in RCA: 20] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/24/2012] [Accepted: 03/14/2013] [Indexed: 10/27/2022]
Abstract
Artemisinin and its derivatives are essential components of artemisinin-based combination therapies for treating severe falciparum malaria. In this paper, we describe the occurrence of haemolysis after oral artemether-lumefantrine treatment. To the best of our knowledge, this is the second reported case of a patient affected by severe falciparum malaria with haemolytic anaemia that is likely associated with oral artemether-lumefantrine treatment.
Collapse
Affiliation(s)
- P De Nardo
- Lazzaro Spallanzani, National Institute for Infectious Diseases-IRCCS, Via Portuense 292, 00179, Rome, Italy.
| | | | | | | | | | | | | | | | | |
Collapse
|
3
|
Di Stasi SM, Giannantoni A, Valenti M, Storti L, Attisani F, Palloni T, Jannini EA, Bibas M, Zampa G. Multicenter, randomized, phase III trial comparing radical retropubic prostatectomy with conventional external beam radiotherapy for localized prostate cancer: An interim report. J Clin Oncol 2006. [DOI: 10.1200/jco.2006.24.18_suppl.4607] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
4607 Background: We report the outcomes of a randomised trial comparing radical retropubic prostatectomy (RP) with conventional external beam radiotherapy (EBRT) in patients with clinically localized prostate cancer. Methods: Between January 1997 and September 2001, 137 patients with clinically localized diagnosed prostate cancer were randomly assigned to RP (n = 70) or EBRT (n = 67). Data collected at follow-up included evidence of clinical disease progression, survival rates and general and disease specific health-related quality of life. All data were measured by physical examination, digital rectal examination, PSA, annual TC and bone scan and questionnaire. Analysis was by intention to treat. Results: After a median follow-up of 67 months (range 24–88) 35 patients (32.8%) had evidence of biochemical disease progression, 22 (31.4%) in RP group and 23 (32.8%) in EBRT group respectively. The median time to biochemical failure was 55.5 months (range 1–86) in RP group and 56 (range 3–88) in EBRT group. A local progression was observed in 11 patients (15.79%) of RP group and 12 (17.9%) of EBRT group. The median time to local progression was 65 months (range 6–86) in RP group and 64 (range 6–88) in EBRT group. Distant metastases were observed in 4 patients (5.7%) in RP group and 6 (8.9%) in EBRT group. The median time to distant failure was 67 months (range 12–86) in RP group and 66 (range 12–88) in EBRT group. Death due to prostate cancer occurred in 3/70 of patients assigned to RP (4.3%) and in 1/67 of those assigned to EBRT (1.5%). A significant decrease in general HRQOL was evident only in the first month after RP (p < 0.001). At 2 years, patients undergoing RP report significantly worse urinary function (p < 0.001), but better bowel function than those treated with EBRT (p < 0.001). Sexual dysfunction was more prevalent in the RP than in the EBRT group (70.2% versus 61.2%). Conclusions: This interim analysis indicates that there was no significant difference between RP and EBRT in terms of clinical disease progression and survival rates in patients with clinically localized prostate cancer. However, additional larger sample size accrual and long-term follow-up data are warranted to confirm these results. No significant financial relationships to disclose.
Collapse
Affiliation(s)
- S. M. Di Stasi
- Tor Vergata University, Rome, Italy; University of Perugia, Perugia, Italy; University of L’Aquila, L’Aquila, Italy; Operative Unit of Urology, Sora (FR), Italy; S. Filippo Neri Hospital, Rome, Italy; S. Giacomo Hospital, Rome, Italy
| | - A. Giannantoni
- Tor Vergata University, Rome, Italy; University of Perugia, Perugia, Italy; University of L’Aquila, L’Aquila, Italy; Operative Unit of Urology, Sora (FR), Italy; S. Filippo Neri Hospital, Rome, Italy; S. Giacomo Hospital, Rome, Italy
| | - M. Valenti
- Tor Vergata University, Rome, Italy; University of Perugia, Perugia, Italy; University of L’Aquila, L’Aquila, Italy; Operative Unit of Urology, Sora (FR), Italy; S. Filippo Neri Hospital, Rome, Italy; S. Giacomo Hospital, Rome, Italy
| | - L. Storti
- Tor Vergata University, Rome, Italy; University of Perugia, Perugia, Italy; University of L’Aquila, L’Aquila, Italy; Operative Unit of Urology, Sora (FR), Italy; S. Filippo Neri Hospital, Rome, Italy; S. Giacomo Hospital, Rome, Italy
| | - F. Attisani
- Tor Vergata University, Rome, Italy; University of Perugia, Perugia, Italy; University of L’Aquila, L’Aquila, Italy; Operative Unit of Urology, Sora (FR), Italy; S. Filippo Neri Hospital, Rome, Italy; S. Giacomo Hospital, Rome, Italy
| | - T. Palloni
- Tor Vergata University, Rome, Italy; University of Perugia, Perugia, Italy; University of L’Aquila, L’Aquila, Italy; Operative Unit of Urology, Sora (FR), Italy; S. Filippo Neri Hospital, Rome, Italy; S. Giacomo Hospital, Rome, Italy
| | - E. A. Jannini
- Tor Vergata University, Rome, Italy; University of Perugia, Perugia, Italy; University of L’Aquila, L’Aquila, Italy; Operative Unit of Urology, Sora (FR), Italy; S. Filippo Neri Hospital, Rome, Italy; S. Giacomo Hospital, Rome, Italy
| | - M. Bibas
- Tor Vergata University, Rome, Italy; University of Perugia, Perugia, Italy; University of L’Aquila, L’Aquila, Italy; Operative Unit of Urology, Sora (FR), Italy; S. Filippo Neri Hospital, Rome, Italy; S. Giacomo Hospital, Rome, Italy
| | - G. Zampa
- Tor Vergata University, Rome, Italy; University of Perugia, Perugia, Italy; University of L’Aquila, L’Aquila, Italy; Operative Unit of Urology, Sora (FR), Italy; S. Filippo Neri Hospital, Rome, Italy; S. Giacomo Hospital, Rome, Italy
| |
Collapse
|
4
|
Andriani A, Zullo A, Di Raimondo F, Patti C, Tedeschi L, Recine U, Caruso L, Bonanno G, Chiarenza A, Lizzani G, Miedico A, Romanelli A, Costa A, Linea C, Marrone C, Mirto S, Mistretta A, Montalbano L, Restivo G, Vinci M, Bibas M, Hassan C, Stella F, Cottone M, Morini S. Clinical and endoscopic presentation of primary gastric lymphoma: a multicentre study. Aliment Pharmacol Ther 2006; 23:721-6. [PMID: 16556173 DOI: 10.1111/j.1365-2036.2006.02826.x] [Citation(s) in RCA: 32] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 12/22/2022]
Abstract
BACKGROUND Although the stomach is the most frequent site of intestinal lymphomas, few data are available on both clinical endoscopic presentation of gastric lymphoma and possible differences between low-grade and high-grade lymphomas. METHODS Clinical, histological and endoscopic records of consecutive patients with primary low-grade or high-grade lymphoma diagnosed were retrieved. Symptoms were categorized as 'alarm' or 'not alarm'. The endoscopic findings were classified as 'normal' or 'abnormal'. RESULTS Overall, 144 patients with primary gastric lymphoma were detected, including 74 low-grade and 70 high-grade lymphoma. Alarm symptoms, particularly persistent vomiting and weight loss, were more frequently present in patients with high-grade lymphoma than in those with low-grade lymphoma (54% vs. 28%; P = 0.002). Low-grade lymphomas presented as 'normal' appearing mucosa (20% vs. 0%; P = 0.0004) or petechial haemorrhage in the fundus (9% vs. 0%; P = 0.02) more frequently than high-grade lymphomas, being also more often confined to the antrum (47% vs. 27%, P = 0.03) and associated with Helicobacter pylori infection (88% vs. 52%, P < 0.0001). On the contrary, high-grade lymphomas presented more commonly as ulcerative type (70% vs. 52%; P = 0.03), being also more frequently diagnosed in stage >I when compared with low-grade lymphomas (70% vs. 21%, P < 0.0001). CONCLUSIONS The overall prevalence of alarm symptoms is quite low and may be absent in more than 70% of patients with low-grade lymphoma.
Collapse
Affiliation(s)
- A Andriani
- Department of Haematology and Gastroenterology, 'San Giacomo' and 'Nuovo Regina Margherita' Hospitals, Rome, Italy
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
5
|
Bibas M, Zampa G, Moscato M. Feasibility of twice-weekly schedule of paclitaxel and carboplatin for solid tumors: A 119 patients study. J Clin Oncol 2004. [DOI: 10.1200/jco.2004.22.90140.2121] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Affiliation(s)
- M. Bibas
- Ospedale San Giacomo Depts of Hematology and Oncology, Roma, Italy; Ospedale Civitavecchia di Roma, Roma, Italy
| | - G. Zampa
- Ospedale San Giacomo Depts of Hematology and Oncology, Roma, Italy; Ospedale Civitavecchia di Roma, Roma, Italy
| | - M. Moscato
- Ospedale San Giacomo Depts of Hematology and Oncology, Roma, Italy; Ospedale Civitavecchia di Roma, Roma, Italy
| |
Collapse
|
6
|
Stroffolini T, Andriani A, Bibas M, Barlattani A. Successful treatment with lamivudine for reactivated hepatitis B infection following chemotherapy for non-Hodgkin's lymphoma. Ann Hematol 2002; 81:48-9. [PMID: 11807636 DOI: 10.1007/s00277-001-0393-8] [Citation(s) in RCA: 15] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/02/2001] [Accepted: 10/01/2001] [Indexed: 10/27/2022]
Abstract
Reactivation of hepatitis B virus (HBV) infection in subjects receiving cytotoxic treatment for non-Hodgkin's lymphoma (NHL) is well documented. This report describes the case of a 69-year-old male chronic HBV carrier who developed severe flare-up of hepatitis B following chemotherapy for large B-cell NHL. Prior to chemotherapy, the patient had normal liver function tests and was negative for HBV DNA by polymerase chain reaction (PCR) assay. HBV reactivation consisted of a rise in hepatic transaminases (peak alanine aminotransferase=1178 IU/ml), hyperbilirubinemia (7.1 mg/dl), and high levels of serum HBV DNA (63.6 x 10(6) copies/ml). A liver biopsy revealed highly active hepatitis and confluent necroses. Lamivudine treatment (100 mg daily) resulted in rapid loss of hepatitis B virus DNA, resolution of hepatitis, and clinical recovery. The patient is still in remission for NHL. Lamivudine is effective in the control of HBV reactivation following chemotherapy.
Collapse
Affiliation(s)
- T Stroffolini
- Department of Hepatology, S. Giacomo Hospital, Via Canova, 29, 00186 Rome, Italy
| | | | | | | |
Collapse
|
8
|
Andriani A, Bibas M, Callea V, De Renzo A, Chiurazzi F, Marcenò R, Musto P, Rotoli B. Autoimmune hemolytic anemia during alpha interferon treatment in nine patients with hematological diseases. Haematologica 1996; 81:258-60. [PMID: 8767532] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/02/2023] Open
Abstract
BACKGROUND. A number of side effects have been observed in patients treated for hematological diseases with alpha-interferon (IFN). In several cases side effects consisted of immunological disorders. Autoimmune hemolytic anemia (AIHA) is the most typical example of an IFN-induced immune-mediated complication. CASE SERIES. In 10 years we observed 9 patients with various hematological disorders who developed AIHA during IFN treatment. The interval between the start of IFN treatment and the onset of acute hemolysis suggests a dual pattern of occurrence: (1) early onset (interval 1 to 21 days), seen in patients who had anti-RBC antibodies before IFN treatment; (2) late onset (interval 3-38 months), in patients with no history of anti-RBC antibodies at the start of treatment. Discontinuation of IFN, often associated with prednisone treatment, caused prompt hematological recovery in all cases; anti-erythrocyte antibodies persisted in the first group of patients and disappeared in the second. CONCLUSIONS. In rare cases IFN may cause AIHA. The immunological derangement caused by IFN seems to act at two different levels: enhanced destruction of antibody-coated RBCs and induction of autoreactive B-cells. As for the possibility of other preexisting immunological disorders, AIHA (even latent) is a contraindication to IFN treatment. Patients treated with IFN need accurate monitoring to guard against for the development of autoimmune disorders.
Collapse
Affiliation(s)
- A Andriani
- Divisione di Medicina, Ospedale San Giacomo, Roma, Italy
| | | | | | | | | | | | | | | |
Collapse
|